First-line treatment patterns and lipid target levels attainment in very high cardiovascular risk outpatients

Lipids in Health and Disease

Volumn 12, Issue 1, 2013, Pages

  Xanthopoulou, Ioanna ^a   Davlouros, Periklis ^a   Siahos, Simos ^a   Perperis, Angelos ^a   Zaharioglou, Evangelia ^a   Alexopoulos, Dimitrios ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

LDL C target attainment; Non HDL C target attainment; Statin; Very high cardiovascular risk

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; ATORVASTATIN PLUS EZETIMIBE; EZETIMIBE; EZETIMIBE PLUS ROSUVASTATIN; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FLUINDOSTATIN; LIPID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY OBSTRUCTION; DIABETES MELLITUS; DRUG CHOICE; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GENDER; GOAL ATTAINMENT; GREECE; HEART INFARCTION; HUMAN; INTRACARDIAC ECHOCARDIOGRAPHY; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTPATIENT CARE; PERCUTANEOUS CORONARY INTERVENTION; PREDICTOR VARIABLE; PRIVATE HOSPITAL; PROSPECTIVE STUDY; PUBLIC HOSPITAL; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; URBAN AREA;

AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GREECE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; OUTPATIENTS; PROSPECTIVE STUDIES; RISK ASSESSMENT; TREATMENT OUTCOME; URBAN POPULATION;

EID: 84887390165     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-12-170     Document Type: Article

References (29)

1. World Health Organization, World Health Statistics 2013 2013 http://www.who.int/mediacentre/factsheets/fs317/en/index.html
2. ESC/EAS Guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the european society of cardiology (ESC) and the European atherosclerosis society (EAS). Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, et al. Eur Heart J 2011 32 1769 1818 21712404
3. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R, Lancet 2010 376 1670 1681 10.1016/S0140-6736(10) 61350-5 21067804
4. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, de Craen AJ, Knopp RH, Nakamura H, Ridker P, et al. BMJ 2009 338 2376 10.1136/bmj.b2376 19567909
5. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D, J Am Coll Cardiol 2008 52 1769 1781 10.1016/j.jacc.2008.08.039 19022156
6. Implications of recent clinical trials for the National cholesterol education program adult treatment panel III guidelines. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ, Circulation 2004 110 227 239 10.1161/01.CIR.0000133317.49796.0E 15249516 (Pubitemid 38924592)
7. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Heart Protection Study Collaborative Group, Lancet 2002 360 7 22 12114036
8. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM, N Engl J Med 2004 350 1495 1504 10.1056/NEJMoa040583 15007110 (Pubitemid 38477774)
9. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J, JAMA 2005 294 2437 2445 10.1001/jama.294.19.2437 16287954 (Pubitemid 41627921)
10. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK, N Engl J Med 2005 352 1425 1435 10.1056/NEJMoa050461 15755765 (Pubitemid 40471450)
11. Results of the national cholesterol education (NCEP) program evaluation project utilizing novel E-technology (NEPTUNE) II survey and implications for treatment under the recent NCEP writing group recommendations. Davidson MH, Maki KC, Pearson TA, Pasternak RC, Deedwania PC, McKenney JM, Fonarow GC, Maron DJ, Ansell BJ, Clark LT, Ballantyne CM, Am J Cardiol 2005 96 556 563 10.1016/j.amjcard.2005.04.019 16098311 (Pubitemid 41132774)
12. A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: the lipid treatment assessment project 2. Santos RD, Waters DD, Tarasenko L, Messig M, Jukema JW, Chiang CW, Ferrieres J, Foody JM, Atherosclerosis 2012 224 150 153 10.1016/j.atherosclerosis.2012.06.052 22818564
13. Diagnosis and management of the metabolic syndrome: an american heart Association/National heart, lung, and blood institute scientific statement. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, et al. Circulation 2005 112 2735 2752 10.1161/CIRCULATIONAHA.105.169404 16157765 (Pubitemid 41532612)
14. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Friedewald WT, Levy RI, Fredrickson DS, Clin Chem 1972 18 499 502 4337382
15. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Waters DD, Brotons C, Chiang CW, Ferrieres J, Foody J, Jukema JW, Santos RD, Verdejo J, Messig M, McPherson R, et al. Circulation 2009 120 28 34 10.1161/CIRCULATIONAHA.108.838466 19546386
16. Achieving optimal lipid goals in patients with coronary artery disease. Karalis DG, Subramanya RD, Hessen SE, Liu L, Victor MF, Am J Cardiol 2011 107 886 890 10.1016/j.amjcard.2010.11.006 21247526
17. Attainment of optional low-density lipoprotein cholesterol goal of less than 70 mg/dl and impact on prognosis of very high risk stable coronary patients: a 3-year follow-up. Rallidis LS, Kotakos C, Sourides V, Varounis C, Charalampopoulos A, Zolindaki M, Dagres N, Papadopoulos C, Anastasiou-Nana M, Expert Opin Pharmacother 2011 12 1481 1489 10.1517/14656566.2011.591379 21651448
18. Centralized Pan-European survey on the undertreatment of hypercholesterolemia in patients using lipid lowering drugs-the CEPHEUS-Greece survey. Elisaf MS, Nikas N, Angiology 2010 61 465 474 10.1177/0003319710366432 20462896
19. Trends in low-density lipoprotein cholesterol goal achievement in high risk United States adults: longitudinal findings from the 1999-2008 national health and nutrition examination surveys. Tattersall MC, Gangnon RE, Karmali KN, Cullen MW, Stein JH, Keevil JG, PLoS One 2013 8 59309 10.1371/journal.pone. 0059309 23565146
20. Physicians' perception of guideline-recommended low-density lipoprotein target values: characteristics of misclassified patients. Sager HB, Linsel-Nitschke P, Mayer B, Lieb W, Franzel B, Elsasser U, Schunkert H, Eur Heart J 2010 31 1266 1273 10.1093/eurheartj/ehq026 20219745
21. low density lipoprotein cholesterol target goal attainment rate and physician perceptions about target goal achievement in Korean patients with diabetes. Hwang JY, Jung CH, Lee WJ, Park CY, Kim SR, Yoon KH, Lee MK, Park SW, Park JY, Diabetes Metab J 2011 35 628 636 10.4093/dmj.2011.35.6.628 22247906
22. Risk for myopathy with statin therapy in high-risk patients. Ballantyne CM, Corsini A, Davidson MH, Holdaas H, Jacobson TA, Leitersdorf E, Marz W, Reckless JP, Stein EA, Arch Intern Med 2003 163 553 564 10.1001/archinte.163.5. 553 12622602 (Pubitemid 36314342)
23. Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis. Mikhailidis DP, Lawson RW, McCormick AL, Sibbring GC, Tershakovec AM, Davies GM, Tunceli K, Curr Med Res Opin 2011 27 1191 1210 10.1185/03007995.2011.571239 21473671
24. Combination therapy with ezetimibe/simvastatin versus statin monotherapy for low-density lipoprotein cholesterol reduction and goal attainment in a real-world clinical setting. Friedman HS, Rajagopalan S, Barnes JP, Roseman H, Clin Ther 2011 33 212 224 10.1016/j.clinthera.2011.02.011 21497705
25. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Stein E, Stender S, Mata P, Sager P, Ponsonnet D, Melani L, Lipka L, Suresh R, Maccubbin D, Veltri E, Am Heart J 2004 148 447 455 10.1016/j.ahj.2004.03.052 15389231 (Pubitemid 39265117)
26. Clinical experience with ezetimibe/simvastatin in a Mediterranean population. Migdalis I, Efthimiadis A, Pappas S, Alexopoulos D, Vlasserou F, Mikhailidis DP, Curr Med Res Opin 2009 25 2571 2576 10.1185/03007990903169031 19739939
27. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Yan AT, Yan RT, Tan M, Hackam DG, Leblanc KL, Kertland H, Tsang JL, Jaffer S, Kates ML, Leiter LA, et al. Am J Med 2006 119 676 683 10.1016/j.amjmed.2005.11.015 16887414 (Pubitemid 44128440)
28. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Gitt AK, Drexel H, Feely J, Ferrieres J, Gonzalez-Juanatey JR, Thomsen KK, Leiter LA, Lundman P, da Silva PM, Pedersen T, et al. Eur J Prev Cardiol 2012 19 221 230 10.1177/1741826711400545 21450578
29. Incidence of and factors associated with achieving target lipid levels in patients with peripheral arterial disease. Banta MR, Ma F, Bravata DM, Kirsner RS, Federman DG, J Gen Intern Med 2006 21 711 714 10.1111/j.1525-1497.2006. 00456.x 16808771 (Pubitemid 43973555)